Arcturus Therapeutics Holdings Inc. (ARCT)

NASDAQ: ARCT · IEX Real-Time Price · USD
19.18
+2.15 (12.62%)
Aug 12, 2022 4:00 PM EDT - Market closed
12.62%
Market Cap 509.74M
Revenue (ttm) 40.57M
Net Income (ttm) -165.48M
Shares Out 26.58M
EPS (ttm) -7.53
PE Ratio n/a
Forward PE 4.44
Dividend n/a
Ex-Dividend Date n/a
Volume 764,025
Open 17.36
Previous Close 17.03
Day's Range 17.36 - 20.18
52-Week Range 11.70 - 58.45
Beta 2.71
Analysts Buy
Price Target 52.30 (+172.7%)
Earnings Date Aug 9, 2022

About ARCT

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vin... [Read more...]

Industry Biotechnology
Founded 2013
Employees 177
Stock Exchange NASDAQ
Ticker Symbol ARCT
Full Company Profile

Financial Performance

In 2021, ARCT's revenue was $12.36 million, an increase of 29.56% compared to the previous year's $9.54 million. Losses were -$203.67 million, 182.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price forecast is 52.3, which is an increase of 172.68% from the latest price.

Price Target
$52.3
(172.68% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 55.43% and 714.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA m...

Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused ...

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -50.39% and 60.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress

Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months afte...

CORRECTING and REPLACING GRAPHIC Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial

Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022

Raymond James analyst doesn't expect Arcturus' COVID-19 vaccine to be authorized in the U.S.

Shares of Acturus Therapeutics Holdings Inc. ARCT, -1.43% were down 2.3% in trading on Wednesday after the company said two doses of its experimental COVID-19 vaccine had an efficacy rate of 55% against...

Arcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam Study

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shared topline data from an ongoing Phase 1/2/3 trial evaluating the ARCT-154, a self-amplifying mRNA COVID-19 vaccine candidate. Results from the effic...

Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase ...

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study

Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 v...

Other symbols: ARGX

Arcturus Therapeutics (ARCT) Surges 7.2%: Is This an Indication of Further Gains?

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference

Could Arcturus Therapeutics Be the Next Moderna?

It's not likely, but it could still end up being a good investment.

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 16.95% and 55.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress

Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on Fe...

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron ...

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Reports Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Trial

Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates targe...